Biogen Inc. (NASDAQ: BIIB) reported third quarter 2023 earnings results today. Total revenue rose 1% year-over-year to $2.53 billion. Revenues grew 3%
Biogen Inc.
-(BIIB)
XNAS:BIIB
BIIB Earnings: A snapshot of Biogen’s Q2 2023 financial results
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the second quarter of 2023. Total
Biogen Inc (BIIB) Q1 2023 Earnings Call Transcript
Biogen Inc (NASDAQ:BIIB) Q1 2023 Earnings Call dated Apr. 25, 2023. Corporate Participants: Chuck Triano -- Head of Investor Relations Christopher Viehbacher -- President and Chief
Everything you need to know about Biogen’s (BIIB) Q1 2023 earnings
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the first quarter of 2023. Total
Biogen, Inc. (BIIB) Q4 2022 Earnings Call Transcript
Biogen, Inc. (NASDAQ: BIIB) Q4 2022 earnings call dated Feb. 15, 2023 Corporate Participants: Michael Hencke -- Head of Investor Relations Christopher A. Viehbacher -- President
Key highlights from Biogen’s (BIIB) Q4 2022 earnings results
Biogen Inc. (NASDAQ: BIIB) reported fourth quarter 2022 earnings results today. Total revenue fell 7% year-over-year to $2.54 billion. Net income attributable
BIIB Stock: Is Biogen an investment worth trying now?
Biogen Inc. (NASDAQ: BIIB) has been going through a rough patch for some time as the company's popular products faced competition and
Biogen Inc. (BIIB) Q3 2022 Earnings Call Transcript
Biogen Inc. (NASDAQ: BIIB) Q3 2022 earnings call dated Oct. 25, 2022 Corporate Participants: Mike Hencke -- Head, Investor Relations Michel Vounatsos -- Chief Executive Officer
Infographic: Highlights from Biogen’s (BIIB) Q3 2022 earnings results
Pharma giant Biogen Inc. (NASDAQ: BIIB) on Tuesday announced financial results for the third quarter of 2022, reporting a double-digit drop in
Biogen Inc. (BIIB) Q2 2022 Earnings Call Transcript
Biogen Inc. (NASDAQ: BIIB) Q2 2022 earnings call dated Jul. 20, 2022 Corporate Participants: Michael Hencke -- Head of Investor Relations. Michel Vounatsos -- Chief Executive
Infographic: Key highlights from Biogen (BIIB) Q2 2022 earnings results
Biogen Inc. (NASDAQ: BIIB) reported second quarter 2022 earnings results today. Total revenue decreased 7% year-over-year to $2.58 billion. Net income attributable
Biogen’s (BIIB) long-term prospects look intact despite Alzheimer’s drug setback
Biogen Inc. (NASDAQ: BIIB) is currently going through a difficult phase as the biotechnology firm’s main products face stiff competition and the
Key highlights from Biogen’s (BIIB) Q1 2022 earnings results
Biogen Inc. (NASDAQ: BIIB) reported first quarter 2022 earnings results today. Total revenue decreased 6% year-over-year to $2.53 billion. GAAP net income attributable
Biogen, Inc. (BIIB) Q4 2021 Earnings Call Transcript
Biogen, Inc. (NASDAQ: BIIB) Q4 2021 earnings call dated Feb. 03, 2022 Corporate Participants: Michael Hencke -- Head of Investor Relations Michel Vounatsos -- Chief Executive
BIIB Earnings: Key quarterly highlights from Biogen’s Q4 2021 financial results
Biogen Inc. (NASDAQ: BIIB) reported fourth quarter 2021 earnings results today. Total revenue decreased 4% year-over-year to $2.73 billion. GAAP net income
Biogen (BIIB) stock research summary | Q3 2021
Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these
Biogen, Inc. (BIIB) Q3 2021 Earnings Call Transcript
Biogen, Inc. (NASDAQ: BIIB) Q3 2021 earnings call dated Oct. 20, 2021 Corporate Participants: Michael Hencke -- Investor Relations Michel Vounatsos -- Chief Executive Officer Alfred
Biogen posts Q3 earnings well above estimates
Biogen (NASDAQ: BIIB) reported third-quarter 2021 financial results before the regular market hours on Wednesday. The company reported Q3 revenue of $2.78
Biogen Inc. (BIIB) Q2 2021 Earnings Call Transcript
Biogen Inc. (NASDAQ: BIIB) Q2 2021 earnings call dated Jul. 22, 2021 Corporate Participants: Mike Hencke -- Director of Investor Relations Michel Vounatsos -- Chief Executive
Biogen (BIIB) Earnings Infographic: Q2 profit, revenue drop but top estimates
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Thursday said its second-quarter earnings and revenues decreased from last year. The results, however, came in
Biogen (BIIB) Stock: Does FDA nod for Aduhelm offer a buying opportunity?
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development